PressRelease
HemoVoid™Advances Multi-omic Study of Thalassemia Severity
MONMOUTHJUNCTION, NJ, February 17, 2026–Anarticle let by researchers from The University of Burdwan, Indiautilized HemoVoid™enrichment in a multi-omic study of thalassemia. The citation is:Mitra, Nibedita, et al. "Multi-omicsanalysis of red blood cells reveals thalassemia severity beyondglobin gene mutations." BloodAdvances (2026):bloodadvances-2025016677.
Thalassemiais classified as transfusion-dependent (TDT), requiring regulartransfusions, and non-transfusion-dependent (NTDT), which follows amilder clinical course. This study aims to identify dysregulatedmolecular pathways in red blood cells contributing to thalassemiaseverity. RNA sequencing and proteome analysis were conducted onisolated RBCs, through Novaseq and Orbitrap MS platform respectively.For proteome analysis, the article states “A 75 µL RBC suspensionwas used for protein extraction with RIPA buffer (Thermo FisherScientific), and hemoglobin was depleted using the HemoVoid Kit(Biotech Support Group, Cat. No. HVB-MS10)”.
TDTsamples exhibited higher protein-to-transcript (PTRs) forferroptosis-related proteins (FTH1, FTL, HMOX1) and lower PTRs forautophagy genes, suggesting impaired cellular recycling and enhancedoxidative cell death. PTR analysis showed reduced cytoskeletal(ankyrin, spectrin) expression, elevated chaperone activity,ferroptosis markers (FTH1, FTL, HMOX1), and suppressed autophagy.Collectively, these multilayered alterations—splicing dysfunction,post-transcriptional deregulation, ferroptosis, autophagysuppression, oxidative stress, and cytoskeletal fragility—underliethe greater disease severity observed in TDT compared with NTDT.
“Thisis an excellent study demonstrating how HemoVoid™ can be used in amulti-omic study comparing different disease severities. TheHemoVoid™ product used in this study is one of many beads derivedfrom our unique NRicher™ surface chemistry platform. With HemoVoid™enrichment, the study was able to differentiate different patientcohorts by protein-to-transcript (PTR) associations. stated Dr.Swapan Roy, President and Founder of Biotech Support Group.
Formore information on HemoVoid™ LC-MS On-Bead, visit:
https://www.biotechsupportgroup.com/HemoVoid-LC-MS...
Formore information of all of our Hemoglobin removal products, visit:
https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm
Formore information on our NRicher™ bead chemistry platform, visit:
https://www.biotechsupportgroup.com/category-s/340.htm
AboutBiotech Support Group LLC
BiotechSupport Group develops innovative sample preparation technologiesthat address the emerging needs of proteomics, biomarker discovery,and personalized medicine. Flagship products include Cleanascite™for lipid removal, AlbuVoid™ and AlbuSorb™ PLUS for serum proteindepletion, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NRicher™ for low abundance, family specific, and targetedproteome enrichment.These products support translational research by simplifyingworkflows and improving sample quality for downstream analysis.
ForBusiness Development Inquiries:
Matthew Kuruc
Phone:732-274-2866
Email: [email protected]
Keywords:HemoVoid™, Hemoglobin depletion, Hemoglobin removal, Thalassemia,Red Blood Cell proteomics, protein-to-transcript (PTR),